abstracts: https://doi.org/10.1182/blood-2018-151
This data as json
| doi | article_title | article_date | session_type | topics | author_names | author_affiliations | first_author_latitude | first_author_longitude |
|---|---|---|---|---|---|---|---|---|
| https://doi.org/10.1182/blood-2018-151 | Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT) | November 29, 2018 | 653. Myeloma: Therapy, excluding Transplantation: Novel Antibody Combinations in Myeloma | ["Peter M. Voorhees, MD", "Cesar Rodriguez, MD", "Brandi Reeves, MD", "Nitya Nathwani, MD", "Luciano J Costa, MD PhD", "Yana Lutska, PharmD", "Daniela Hoehn, MDPhD", "Huiling Pei, PhD", "Jon Ukropec, PhD", "Ming Qi, MD PhD", "Thomas Lin, MD PhD", "Paul Richardson"] |